Notwithstanding various setbacks, quite a few MDM2 inhibitors have now progressed into late-phase clinical progress. New tactics have also been designed to enhance the efficacy of MDM2 inhibitors also to mitigate their on-goal toxicity. On this review, we summarize the development and challenges in the development of the MDM2 targeted https://lorenzoezsjz.iyublog.com/31094977/abbv-744-no-further-a-mystery